大发国际

R&D Pipeline

Guided by innovation and internationalization, Fosun Pharma increases its investment in R&D and the introduction of scientific research personnel, enriches its innovative product pipelines, improves its R&D and clinical trial capacities for new drugs, and speeds up the R&D and transformation of innovative technologies and products through diverse and multi-level cooperation models, such as independent R&D, co-development, in-licensing, and in-depth incubation.

Main pipelines

Data as of the end of 2022, Fosun Pharma had more than 260 pipelines under development, including innovative drugs, biosimilars, generic drugs and those for consistency evaluation.

  • 6
    self-developed innovator drugs (indications)
  • 4
    license-in innovator drugs (indications)
  • 27
    generic drugs (indications) of Fosun Pharma were approved for marketing in Chinese mainland/Hong Kong, China/United States
  • 7
    innovator drugs (indications)
  • 30
    generic drugs (indications) were applied for marketing in the Chinese mainland (NDA)
  • 22
    innovator drugs (indications) were approved for clinical trials (IND) in the Chinese mainland.
网站地图
友情链接:ag亚娱集团  尊龙凯时  尊龙凯时  9888浏览器拉斯维加斯客服  尊龙凯时人生就是博  im电竞APP下载  海博测评  尊龙凯时  九州ku酷游  918博天堂  凯时登录  尊龙凯时官网  尊龙凯时官网  尊龙凯时人生就是博  大发国际